Dyax Corp. And Genzyme Corporation Initiate Pivotal Phase III Trial Of Subcutaneously Administered DX-88 For The Treatment Of Hereditary Angioedema

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 8, 2005--Dyax Corp. (Nasdaq:DYAX) and Genzyme Corporation (Nasdaq:GENZ) announced today that patient treatment has begun in their pivotal Phase III clinical trial of Dyax's recombinant plasma kallikrein inhibitor known as DX-88. In this trial, referred to as EDEMA3, DX-88 is being studied for the treatment of patients with hereditary angioedema (HAE), a rare, genetic disease that causes acute attacks of localized swelling and inflammation.